Antioxidant and Cytotoxicity Potential of Piperine and Sorafenib combination in human MDA-MB-231 Breast Cancer cells
Mohany, H., Mahmoud, M., El-Shehawy, A., Gaber, M., Elmetwalli, A., Salama, A., El Sewedy, T. (2021). Antioxidant and Cytotoxicity Potential of Piperine and Sorafenib combination in human MDA-MB-231 Breast Cancer cells. EKB Journal Management System, 17(1), 108-116. doi: 10.21608/blj.2021.200558
Hany Mohany; Mohammad A. Mahmoud; Ashraf A. El-Shehawy; Mohamed Gaber; Alaa Elmetwalli; Afrah F. Salama; Tarek El Sewedy. "Antioxidant and Cytotoxicity Potential of Piperine and Sorafenib combination in human MDA-MB-231 Breast Cancer cells". EKB Journal Management System, 17, 1, 2021, 108-116. doi: 10.21608/blj.2021.200558
Mohany, H., Mahmoud, M., El-Shehawy, A., Gaber, M., Elmetwalli, A., Salama, A., El Sewedy, T. (2021). 'Antioxidant and Cytotoxicity Potential of Piperine and Sorafenib combination in human MDA-MB-231 Breast Cancer cells', EKB Journal Management System, 17(1), pp. 108-116. doi: 10.21608/blj.2021.200558
Mohany, H., Mahmoud, M., El-Shehawy, A., Gaber, M., Elmetwalli, A., Salama, A., El Sewedy, T. Antioxidant and Cytotoxicity Potential of Piperine and Sorafenib combination in human MDA-MB-231 Breast Cancer cells. EKB Journal Management System, 2021; 17(1): 108-116. doi: 10.21608/blj.2021.200558

Antioxidant and Cytotoxicity Potential of Piperine and Sorafenib combination in human MDA-MB-231 Breast Cancer cells

Biochemistry Letters
Article 10, Volume 17, Issue 1, 2021, Page 108-116  XML PDF (567.18 K)
Document Type: Original Article
DOI: 10.21608/blj.2021.200558
View on SCiNiTO View on SCiNiTO
Authors
Hany Mohany1; Mohammad A. Mahmoud1; Ashraf A. El-Shehawy1; Mohamed Gaber2; Alaa Elmetwalliorcid 3; Afrah F. Salama4; Tarek El Sewedy5
1Department of Chemistry, Faculty of Science, Kafr el sheikh University.
2Chemistry Department, Faculty of Science, Tanta University
3Department of Clinical Trial Research Unit and Drug Discovery, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.
4Biochemistry Section, Chemistry Department, Faculty of Science, Tanta University.
5Department of Applied Medical Chemistry, Medical Research Institute, Alexandria University
Abstract
Background: Breast cancer is the most common cancer diagnosed in women. Worldwide, it is the second most common cause of cancer-related mortality among women. Plants have been the primary sources of natural product drug discovery, over 60% of the current anticancer drugs were derived from natural sources. Piperine (PIP) is a major bioactive constituent of the black pepper (Piper nigrum). Aim: We have assessed  the cytotoxicity of PIP and the anti-hepatocellular carcinoma drug Sorafenib (SOR) against human triple negative breast cancer MDA-MB-321 cell line. Furthermore, we have investigated the potential effect of single and their combined treatment on antioxidant enzyme activity and lipid peroxidation status. Methods: We measured cytotoxicity of PIP and SOR in MDA-MB-321 cells by MTT assay after 48 hours treatment. Activity of the antioxidant enzymes superoxide dismutase (SOD), catalase (CAT) and the lipid peroxidation marker Malondialdehyde (MDA) were measured colorimetrically. Results: Both PIP and SOR caused a significant (P<0.001) dose dependent cell death in MDA-MB-321 cells. However, SOR showed higher cytotoxicity (IC90= 144.8 ± 5.1µg/ml) compared to PIP (IC90= 252.4 ± 6.7µg/ml). Consistent with these data, SOR individual treatment caused the highest significant SOD and CAT activities while their combined treatment caused the lowest MDA levels (4.2 ± 0.2 nmol/ml) compared with the control untreated (7.7 ± 0.2 nmol/ml) or DMSO treated cells (7.76 ± 0.25 nmol/ml).
Conclusion: This study points out a potential mode of action for PIP and SOR as anticancer agents in triple negative breast cancer cells through the regulation of their antioxidant and lipid peroxidation status.
Keywords
Piperine; sorafenib; lipid peroxidation; antioxidants; breast cancer
Statistics
Article View: 462
PDF Download: 277